Major
Probable
Açıklama
Aripiprazole acts as a partial D2 agonist/antagonist and can oppose levodopa's dopaminergic therapy, worsening Parkinson's disease symptoms.
Mekanizma
Aripiprazole's partial D2 agonism results in net D2 receptor blockade in the context of high dopamine from levodopa therapy, impairing motor function.
Klinik Önemi
Parkinson's patients treated with dopaminergic therapy can experience marked motor deterioration when any D2-acting antipsychotic is initiated.
Yönetim
Avoid aripiprazole in Parkinson's disease; use medications with minimal D2 blockade for psychosis treatment in these patients.